Navigation Links
Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
Date:8/21/2008

PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the lead compounds of its Aurora kinase and VEGFR dual inhibitor program met a significant development milestone. Aurora kinase is a critical signaling enzyme whose function is required for cancer cell division, while vascular endothelial growth factor receptor (VEGFR) plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. Telik's lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR. A development drug candidate is being selected, and assuming successful completion of preclinical studies, a Phase 1 clinical study may be initiated.

"Our computational TRAP(R) technology enabled us to combine and process information on the properties of single target molecules resulting in compounds with the desired dual target mechanism of action," said Steve Schow, Ph.D., Vice President of Research at Telik. "The ability to inhibit two targets may reduce the ability of cancer cells to evade the inhibition of one target alone and results in a better outcome."

The initial data demonstrating the activity of Telik's lead compounds was presented at the EORTC-AACR-NCI Meeting held in Belgium in the fourth quarter of 2007.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemothera
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
3. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
6. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
7. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
9. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
10. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
11. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 Isagenix International, a leading global health ... three Silver, and three Bronze Stevie® Awards at the ... Chicago this month.The American Business ... program in the U.S. "Winning is ... developing leaders, cultivating talent, creating a unified team, and ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Apex Therapeutics ... BIO International Convention in Philadelphia, PA. , The presentation took place on ... outlined the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... 2015 R-Japan Co.,Ltd. obtained the license of cell ... Medicine from the Ministry of Health, Labour and Welfare Kinki ... The fact that R- Japan ... from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, ... provide stem cell manufacturing service to medical institutions. As of ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... (AFM) is hosting a webinar to provide advanced scientific research into new classes ... bio science and energy. Touted as 'the wonder material of the 21st ...
Breaking Biology Technology:Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... N.J., Oct. 6, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... today announced that the Company submitted its plan to ... standard of the New York Stock Exchange ("NYSE") on ... Bioengineering, Inc. American Oriental Bioengineering, Inc. ...
... and TORONTO, Oct. 6, 2011 Generex Biotechnology ... Antigen Express, Inc. ( www.antigenexpress.com ), today announced ... Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference ... York Academy of Medicine in New York City. ...
... SANTA CLARA, Calif., Oct. 6, 2011 ProteinSimple ... next-generation platform for quality control monitoring of protein-based ... the CE Pharm 2011 conference, October 9-13, 2011, ... protein-based therapeutics must monitor product purity closely. Imaged ...
Cached Biology Technology:Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine 2Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine 3Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine 4Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine 5ProteinSimple Launches New System for Protein Biologics 2
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Sharp has selected its industry-leading Natural ... its latest flagship smartphone device, the AQUOS ZETA ... shipments of its fingerprint ID sensor technology, this ... and leadership in the biometrics market through its ...
(Date:6/23/2015)... 2015   MedNet Solutions , an innovative ... spectrum of clinical research, is pleased to announce ... the company,s intuitive, flexible and affordable cloud-based eClinical ... Stevie® Award by the American Business Awards ... category.  The American Business Awards are considered the ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... the University of Hawaii, the Wildlife Conservation Society, ... Projecto Meros do Brazil discovered a new species of ... length and can weigh nearly 1,000 pounds. This newly ... of the Eastern Pacific Ocean. Was the ...
... Capital Leads Round with Additional Funding by Syncom ... Lockheed Martin, GE Security, Baker Capital and ... the fast pass for airport,security, has secured $44.4 million ... round also includes a second investor Syncom Venture,Partners, and ...
... have created a tiny motorized ,positioning device that has ... applications that include biological sensors and more ,compact, powerful ... comb drive, might be used as a ,"nanoscale manipulator" ... devices also can be used in watery environments for ...
Cached Biology News:Genetics reveals big fish that almost got away 2Clear(R) Secures $44.4 Million in Venture Funding 2Clear(R) Secures $44.4 Million in Venture Funding 3New 'nano-positioners' may have atomic-scale precision 2New 'nano-positioners' may have atomic-scale precision 3
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Ms anti-Cyclophilin D...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Biology Products: